Molecular pathways and related target therapies in liver carcinoma

Current Pharmaceutical Design

Volumn 13, Issue 32, 2007, Pages 3279-3287

  Tommasi, S ^a   Pinto, R ^a   Pilato, B ^a   Paradiso, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cellular pathways; Hepatocarcinoma; Molecular alterations; Target therapies

Indexed keywords

4 N ACETYLDINALINE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 ETHYNYLURACIL; 6 HYDROXYMETHYLACYLFULVENE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CYTARABINE; DIFLOMOTECAN; EPIRUBICIN; ERLOTINIB; FLUDARABINE; FLUOROURACIL; GANCICLOVIR; GEFITINIB; GEMCITABINE; GSK 572016; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LAPATINIB; MB 07133; MG 115; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NOLATREXED; ONCOLYTIC VIRUS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; SORAFENIB; THYMIDINE KINASE; THYMIDYLATE SYNTHASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CELL CYCLE REGULATION; CELL INVASION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DRUG ACETYLATION; DRUG POTENTIATION; DRUG TARGETING; GENE THERAPY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ACETYLATION; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DNA; DNA METHYLATION; EPIGENESIS, GENETIC; GENE THERAPY; HISTONES; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 36749028203     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782360663     Document Type: Review

References (98)

1. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-42.
2. Taub R. Liver regeneration: From myth to mechanism. Nat Rev Mol Cell Biol 2004; 5: 836-47.
3. Mansour M, Touka M, Malena A, Indiveri C, Dong W, Gionfriddo I, et al. Human papillomavirus type 77 E7 protein is a weak de-regulator of cell cycle. Cancer Lett 2007; 246: 274-81.
4. Paradiso A, Ranieri G, Stea B, Zito A, Zehbe I, Tommasino M, et al. Altered p16INK4a and Fhit expression in carcinogenesis and progression of human oral cancer, Int J Oncol 2004; 24: 249-55.
5. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35: 266-9.
6. Yuan JM, Govindarjan S, Ross RK, Yu MC. Chronic infection with hepatitis G virus in relation to hepatocellular carcinoma among non-Asians in Los Angels County, California. Cancer 1999; 86: 936-43.
7. Aoki H, Kajino K, Arakawa Y, Hino O. Molecular cloning of a rat chromosome putative recombinogenic sequence homologous to the hepatitis B virus encapsidation signal. Proc Natl Acad Sci USA 1996; 93: 7300-4
8. Dejean A, Bougueleret L, Grzeschik KH, Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 1986; 322: 70-2.
9. Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343: 555-7.
10. Graef E, Caselmann WH, Wells J, Koshy R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994; 9: 81-7.
11. Diao J, Khine AA, Sfrangi F, Hssu E, Iorio C, Tibbles LA, et al. X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem 2001; 276: 8328-40.
12. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: A systematic review of the epidemiologic evidence. Oncogene 2006; 25: 3756-70.
13. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006; 11: 469-87.
14. Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 2006; 25: 5581-90.
15. Parrella P, Scintu M, Prencipe M, Poets ML, Gallo AP, Rabitti C, et al. HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast. Cancer Lett 2005; 222: 75-81.
16. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004; 10: 5349-54.
17. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, et al. Inactivation of p161NK4 in hepatocellular carcinoma. Hepatology 1996; 24: 575-9.
18. Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, et al. Methylation Status of Genes Upregulated by Demethylating Agent 5-aza-2′-Deoxycytidine in Hepatocellular Carcinoma. Oncology 2007; 71: 77-85.
19. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, et al. Historic deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006; 15: 227-30.
20. Wakabayashi K, Saito H, Kaneko F, Nakamoto N, Tada S, Hibi T. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int J Oncol 2005; 26: 233-9.
21. Acharya MR, Karp JE, Sausville EA, Hwang K, Ryan Q, Gojo I, et al. Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006; 24: 367-75.
22. Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: Results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006; 17: 1096-102
23. Stuart K, Tessitore J, Rudy J, Clendennin N, Jonston A. A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.Cancer 1999; 86: 410-4.
24. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13-26.
25. Humphreys MJ, Ghaneh P, Greenhalf W, Campbell F, Clayton TM, Everett P, et al. Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases. Gene Ther 2001; 8: 1241-7.
26. Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adeno viral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000; 31: 606-14.
27. Tommasi S, Fedele V, Lacalamita R, Crapolicchio A, Perlino E, Bellizzi A, et al. Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 2004; 209: 215-22.
28. Benz CC, Fedele V, Xu F, Ylstra B, Ginzinger D, Yu M, et al. Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. Genes Chromosomes Cancer 2006; 45: 983-94.
29. Zhao YN, Cao J, Wu FX, Ou C, Yuan WP, Mo QG, et al. Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Ai Zheng 2004; 23: 762-6.
30. Xu JM, Li YM, Wang Y, Zhao CH, Yuan SJ, Yang WW, et al. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan] Zhonghua Zhong Liu Za Zhi 2006; 28: 578-82.
31. Giannelli G, Azzariti A, Sgarra C, Porcelli L, Antonaci S, Paradiso A. ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 479-85.
32. Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, et al. The clinical value of the hepatocyte growth factor and its receptor c-met for liver cancer patients with hepatectomy. Dig Liver Dis 2006; 38: 490-7.
33. Fan S, Ma YX, Gao M, Yuan RQ, Meng Q, Goldberg ID, et al. The multisubstrate adapter Gabl growth factor (scatter factor)-c.met signalling for cell survival and DNA repair. Mol Cell Biol 2001; 21: 4968-84.
34. Dufour JF. Met-thodology. J Hepatol 2007; 46: 748-49.
35. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005; 11: 2312-9.
36. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65: 1479-88.
37. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Metdependent human tumors. Cancer Res 2006; 66: 1721-9.
38. Hussein NA, El-Sayed HH, El-Khayat HR, Zahran NM. Assessment of platelet activation in coupled schistosomiasis and viral hepatitis infection: contribution to complexity of course and development of complications. J Egypt Soc Parasitol 2006; 36: 845-66.
39. Eckel F, von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and ádvanced hepatocellular carcinoma. Oncology 2005; 69: 363-71.
40. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/ PRF/5. Cancer Res 2006; 66: 11851-8.
41. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-90.
42. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-7.
43. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 2001; 92: 136-45.
44. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-15.
45. Zucman-Rossi J, Jeannot E, Tran Van Nhieu J, Scoazec J-Y, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology 2006; 43: 515-24.
46. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatoceltular carcinomas. Clin Cancer Res 2001; 7: 594-9.
47. Yuan Y, Wang J, Li J, Wang L, Li K Yang Z, et al. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 2006; 12: 6687-95.
48. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mut.ations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXINI. Nat Genet 2000; 24: 245-50.
49. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad SciUSA 2004; 101: 12682-7.
50. Fujie H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, Makuuchi M, et al. Frequent beta-catenin aberration in human hepatocellular carcinoma. Hepatol Res 2001; 20: 39-51.
51. Sridhar SS, Hedley U, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4: 677-85.
52. Zangari M, Cavallo F, Tricot G. Farnesyltransferase inhibitors and rapamycin in the treatment of multiple mieloma. Curr Pharm Biotechnol 2006; 7: 449-53.
53. Carloni V, Vizzutti F, Pantaleo P. Famesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. Clin Cancer Res 2005; 11: 4266-74.
54. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004; 9: 667-76.
55. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-37.
56. Adjei AA, Hidalgo M. Intracellular signal transdaction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23: 5386-403.
57. Zhang YJ, Rossner P Jr, Chen Y, Agrawal M, Wang Q, Wang L, et al. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer 2006; 119: 985-91.
58. Edamoto Y, Hara A, Biemat W, Terracciano L, Cathomas G, Richle H-M, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334-41.
59. Zhang C, Li Z, Cheng Y, Jia F, Li R, Wu M, et al. CpG island methylator phenotype association with elevated senim alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 944-52
60. Wu XM, Fu JG, Ge WZ, Zhu JY, Wang JY, Zhang W, et al. Screen p53 mutations in hepatocellular carcinoma by FASAY: A novel splicing mutation. J Zhejiang Univ Sci B 2007; 8: 81-7.
61. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. MJA 2000; 173: 403-5.
62. Xu GW, Sun ZT, Forrester Y, Wang XW, Cousen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 1996; 24: 1264-8.
63. Warren RS, Kim DH. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg Oncol Clin N Am 2002; 11: 571-88.
64. Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002; 123: 608-18.
65. Liu K, Lei XZ, Zhao LS, Tang H, Liu L, Feng P, et al. Tissue microarray for high-throughput analysis of gene expression profiles in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1369-72.
66. Katoh H, Shibata T, Kokubu A, Ojima H, Fukayama M, Kanai Y, et al. Epigenetic instability and chromosomal instability in hepatocellular carcinoma. Am J Pathol 2006; 168: 1375-84.
67. Laurent-Puig P, Ligoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocareinogenesis. Gastroenterology 2001; 120: 1763-73.
68. Jin M, Piao Z, Kim NG, Park C, Shin EC, Park JH, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000; 89: 60-8.
69. Lozano G, Zambetti GP. Gankyrin: An intriguing name for a novel regulator of p53 and RB. Cancer Cell 2005; 8: 3-4.
70. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/ gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2002; 8: 638-43.
71. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo H, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005; 8: 75-87.
72. Miyashita K, Shiraki K, Fuke H, Inoue T, Yamanaka Y, Yamaguchi Y, et al. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 2006,18: 249-56.
73. Jung HY, Park SH, Yoo YD, Kim JS, Kim YH. CDK2/4, regulate retinoic acid-induced G1 arrest in hepatocellular carcinoma cells. Hepatol Res 2005; 31: 143-52.
74. Inoue T, Shiraki K, Fuke H, Yamanaka Y, Miyashita K, Yamaguchi Y, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs 2006; 17: 261-8.
75. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002; 62: 5443-50.
76. Wallace HM, Fraser AV. Polyamine analogues as anticancer drugs. Biochem Soc Trans 2003; 31: 393-6.
77. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, et al. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 2005; 312: 554-60.
78. Kim D. Oncolytic virotherapy for cancer with the adenovirus d11520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 2001; 1: 525-38.
79. Habib NA, Sarraf CE, Mitry RR, Haylik R, Nicholls J, Kelly M, et al. E1B-deleted adenovinis (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12: 219-26.
80. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrase Khar S, Chiocca EA, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-5.
81. Thompson EW, Newgreen DF, Taria D. Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5.
82. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65.
83. Calvisi DF, Ladu S, Conner EA, Factor VM, Thorgeirsson SS. Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest 2004; 84: 1137-47.
84. Bachelder RE, Yoon SO, Franci C, Garcia de Herreros A, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial-mesenchymal transition. J Cell Biol 2005; 168: 29-33.
85. Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003; 201: 250-9.
86. Giannelli G, Bergamini C, Franseva E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta 1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005; 129: 1375-83.
87. Peinado H, Quintanilla M, Cano A. Transforming growth factor-beta 1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278: 21113-23.
88. Schuppan D, Ocker M. Integrin-mediated control of cell growth. Hepatology 2003; 38: 289-91.
89. Zhang H, Ozaki I, Mizuta T, Yoshimura T, Matsuhashi S, Hisatomi A, et al. Transforming growth factor-beta 1-induced apoptosis is blocked by beta 1-integrin-mediated mitogen-activated protein kinase activation in human hepatoma cells.Cancer Sci 2004; 95: 878-86.
90. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hapatocellular carcinoma. Cancer Res 2000; 60: 1394-402.
91. Cai T, Lei QY, Wang LY, Zha XL. TGF-beta 1 modulated the expression of alpha 5 beta 1 integrin and integrin-mediated signaling in human hepatocarcinoma cells. Biochem Biophys Res Commun 2000; 274: 519-25.
92. Ji GZ, Wang XH, Miao L, Liu Z, Zhang P, Zhang FM, et al. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12: 644-8.
93. Carillo MC, Alvarez Mde L, Quiroga AD. Interferon alfa-2b triggers transforming growth factor-beta-induced apoptosis on preneoplastic liver. Ann Hepatol 2006; 5: 244-50.
94. Cho IJ, Kim SH, Kim SG. Inhibition of TGFb1-mediated PAI-1 induction by oltipraz through selective interruption of Smad 3 activation. Cytokine 2006; 35: 284-94.
95. Zhao C, Chen W, Yang L, CEen L, Stephen A. Stimpson, et al. PPARγ Agonists Prevent TGFβ1/Smad3-Signaling in Human Hepatic Stellate Cells. Biochem Biophys Res Commun 2006; 35: 385-91.
96. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Curr Pharm Des 2006; 12(1): 111-28.
97. Ferrandi M, Barassi P, Molinari I, Torielli L, Tripodi G, Minotti E, et al. Ouabain antagonists as antihypertensive agents. Curr Pharm Des 2005; 11(25): 3301-5.
98. Longo R, Torino F, Gasparini G. Targeted therapy of breast cancer. Curr Pharin Des 2007; 13(5): 497-517.